115 related articles for article (PubMed ID: 33090201)
1. Effect of Consecutive Alternating Administration of a Triple Combination of Anti-Enteroviral Compounds in Mice Infected with Coxsackievirus B3.
Stoyanova A; Galabov AS
Pathog Dis; 2020 Nov; 78(9):. PubMed ID: 33090201
[TBL] [Abstract][Full Text] [Related]
2. Anti-enteroviral triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Pürstinger G; Dobrikov G; Dimitrov V; Philipov S; Galabov AS
Antivir Chem Chemother; 2015 Dec; 24(5-6):136-147. PubMed ID: 27815331
[TBL] [Abstract][Full Text] [Related]
3. Effect of consecutive alternating administration (CAA) of a triple anti-enteroviral combination on Coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Galabov AS
Antiviral Res; 2015 Sep; 121():138-44. PubMed ID: 26196747
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the Consecutive Alternating Administration Course of a Triple Antiviral Combination in Coxsackievirus B3 Infections in Mice.
Vassileva-Pencheva R; Galabov AS
Drug Res (Stuttg); 2016 Dec; 66(12):639-643. PubMed ID: 27552486
[TBL] [Abstract][Full Text] [Related]
5. Consecutive alternating administration as an effective anti-coxsackievirus B3 in vivo treatment scheme.
Stoyanova A; Galabov AS
Arch Virol; 2021 Jul; 166(7):1869-1875. PubMed ID: 33877422
[TBL] [Abstract][Full Text] [Related]
6. Genome analysis of coxsackievirus B1 isolates during the consecutive alternating administration course of triple antiviral combination in newborn mice.
Grozdanov P; Joffret ML; Stoyanova A; Polston P; Achouri E; Nikolova I; Delpeyroux F; Galabov AS
Antivir Chem Chemother; 2020; 28():2040206620906061. PubMed ID: 32041425
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of RNA Helicase Activity Prevents Coxsackievirus B3-Induced Myocarditis in Human iPS Cardiomyocytes.
Yun SH; Shin HH; Ju ES; Lee YJ; Lim BK; Jeon ES
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344926
[TBL] [Abstract][Full Text] [Related]
8. Effects of double combinations of enterovirus replication inhibitors against Coxsackie B viruses.
Stoyanova A; Galabov AS
Acta Virol; 2021; 65(4):411-419. PubMed ID: 34978843
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
[TBL] [Abstract][Full Text] [Related]
10. Activity of pleconaril against enteroviruses.
Pevear DC; Tull TM; Seipel ME; Groarke JM
Antimicrob Agents Chemother; 1999 Sep; 43(9):2109-15. PubMed ID: 10471549
[TBL] [Abstract][Full Text] [Related]
11. Avoiding drug-resistance development by novel approach of combining anti-enteroviral substances against coxsackievirus B1 infection in mice.
Vassileva-Pencheva R; Galabov AS
Antiviral Res; 2010 Feb; 85(2):366-72. PubMed ID: 19900482
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Combination Approach as a Perspective to Combat Enterovirus Infections.
Galabov AS; Nikolova I; Vassileva-Pencheva R; Stoyanova A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):91-9. PubMed ID: 27442375
[TBL] [Abstract][Full Text] [Related]
13. Lithium chloride confers protection against viral myocarditis via suppression of coxsackievirus B3 virus replication.
Zhao Y; Yan K; Wang Y; Cai J; Wei L; Li S; Xu W; Li M
Microb Pathog; 2020 Jul; 144():104169. PubMed ID: 32205210
[TBL] [Abstract][Full Text] [Related]
14. The Evolution of Pleconaril: Modified
Volobueva A; Egorova A; Galochkina A; Ekins S; Zarubaev V; Makarov V
Molecules; 2020 Mar; 25(6):. PubMed ID: 32188089
[TBL] [Abstract][Full Text] [Related]
15.
Lee YG; Park JH; Jeon ES; Kim JH; Lim BK
J Microbiol Biotechnol; 2016 Nov; 26(11):2012-2018. PubMed ID: 27558433
[TBL] [Abstract][Full Text] [Related]
16. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3.
Schmidtke M; Wutzler P; Zieger R; Riabova OB; Makarov VA
Antiviral Res; 2009 Jan; 81(1):56-63. PubMed ID: 18840470
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.
Zhou L; He X; Gao B; Xiong S
J Virol; 2015 Oct; 89(20):10512-23. PubMed ID: 26269170
[TBL] [Abstract][Full Text] [Related]
18. Early Treatment of Coxsackievirus B3-Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy.
Pinkert S; Dieringer B; Klopfleisch R; Savvatis K; Van Linthout S; Pryshliak M; Tschöpe C; Klingel K; Kurreck J; Beling A; Fechner H
Circ Heart Fail; 2019 Nov; 12(11):e005250. PubMed ID: 31718319
[TBL] [Abstract][Full Text] [Related]
19. Antiviral treatment of Coxsackie B virus infection in human pancreatic islets.
Berg AK; Olsson A; Korsgren O; Frisk G
Antiviral Res; 2007 Apr; 74(1):65-71. PubMed ID: 17239967
[TBL] [Abstract][Full Text] [Related]
20. Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice.
Stein EA; Pinkert S; Becher PM; Geisler A; Zeichhardt H; Klopfleisch R; Poller W; Tschöpe C; Lassner D; Fechner H; Kurreck J
J Infect Dis; 2015 Feb; 211(4):613-22. PubMed ID: 25193982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
